ERBB2 and breast carcinoma: This study has also included an ultra-low HER2 classification (HER2 IHC >0 and IHC<1+), a group that may also benefit as demonstrated in the DAISY trial, a phase II study evaluating T-DXd across all levels of HER2 expression in patients with metastatic/unresectable breast cancer.